Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

Positive Phase 3 trial for Fabry disease courtesy of Amicus

 (Image source: nasdaq.com)

Shares of biopharmaceutical company Amicus Therapeutics, Inc. (NASDAQ:FOLD) are soaring in the early session of trading after the company revealed positive results from a Phase 3 clinical trial treatment of Fabry disease. Fabry disease is rare disorder that prevents that body from producing enough enzymes to metabolize GL-3. GL-3 composes of sugar and fat. The drug treatment developed for Fabry disease is called migalastat. Patients who were given migalastat saw a reduction in GL-3 and “statistically significant improvement in kidney functions”.